SpectRx granted patent for non-invasive cervical cancer detection technology

By Lisa Kerner

Erie, Pa., March 9 - SpectRx, Inc. said it was granted a patent (U.S. 7,006,220) for the method in which its non-invasive cervical cancer detection technology helps define the location of disease and reduce errors in data collection.

"This patent is an important addition to our portfolio of non-invasive detection and monitoring intellectual property," Guided Therapeutics, Inc. president and chief operating officer Mark Faupel said in a company news release. Guided Therapeutics is the SpectRx subsidiary formed to commercialize the cancer detection device.

"The patent provides for a more efficient method of determining tissue characteristics and may be useful for detecting cervical disease and possibly other cancers as well," Faupel added.

Currently undergoing Food and Drug Administration pivotal clinical trials, the device uses proprietary technology to painlessly identify cancers by analyzing light reflected from the cervix. An image of the cervix is created highlighting the location and severity of disease.

According to SpectRx, the technology distinguishes between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level.

Cervical cancer is the third most common cancer among women worldwide, with about 471,000 cases diagnosed annually, the release stated.

Based in Norcross, Ga., SpectRx is a diabetes management company that develops solutions for insulin delivery and glucose monitoring.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.